{"id":46293,"date":"2025-11-11T11:21:15","date_gmt":"2025-11-11T03:21:15","guid":{"rendered":"https:\/\/flcube.com\/?p=46293"},"modified":"2025-11-11T11:21:16","modified_gmt":"2025-11-11T03:21:16","slug":"hangzhou-bio%e2%80%91sincerity-secures-nmpa-approval-for-bios%e2%80%910625-tablet-first%e2%80%91in%e2%80%91class-ulcerative-colitis-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=46293","title":{"rendered":"Hangzhou Bio\u2011Sincerity Secures NMPA Approval for BIOS\u20110625 Tablet \u2013 First\u2011in\u2011Class Ulcerative Colitis Therapy"},"content":{"rendered":"\n<p><strong>Hangzhou Bio\u2011Sincerity Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/301096:SHE\">SHE: 301096<\/a>) announced today that its <strong>BIOS\u20110625<\/strong> tablet, a <strong>Class\u202f1 small\u2011molecule innovative drug<\/strong>, has received <strong>clinical trial approval<\/strong> from China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> for the treatment of <strong>ulcerative colitis (UC)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-amp-development-highlights\">Deal &amp; Development Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug<\/strong><\/td><td>BIOS\u20110625 (tablet)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Ulcerative colitis (moderate\u2011to\u2011severe)<\/td><\/tr><tr><td><strong>Regulatory Milestone<\/strong><\/td><td>NMPA clinical\u2011trial authorization (Phase\u202fI\/II)<\/td><\/tr><tr><td><strong>Mechanism of Action<\/strong><\/td><td>Novel, first\u2011in\u2011class target not addressed by any approved UC therapy worldwide<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Hangzhou Bio\u2011Sincerity (SHE:\u202f301096)<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>11\u202fNov\u202f2025<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Initiate Phase\u202fI safety study in China, followed by Phase\u202fII efficacy trials; potential global IND filing in 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-scientific-amp-market-context\">Scientific &amp; Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet Need:<\/strong> Current UC treatments (5\u2011ASA, biologics, JAK inhibitors) do not address the <strong>new molecular pathway<\/strong> targeted by BIOS\u20110625, leaving a therapeutic gap for patients who are refractory or intolerant to existing options.<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> No approved small\u2011molecule drugs worldwide target this mechanism, giving Bio\u2011Sincerity a <strong>first\u2011to\u2011market advantage<\/strong> if clinical data confirm efficacy and safety.<\/li>\n\n\n\n<li><strong>Strategic Impact:<\/strong> The NMPA approval validates Bio\u2011Sincerity\u2019s <strong>in\u2011house discovery platform<\/strong> and positions the company to attract <strong>partnering interest<\/strong> from multinational pharma seeking novel UC assets.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-amp-investor-implications\">Financial &amp; Investor Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>R&amp;D Funding:<\/strong> The company plans to allocate <strong>RMB\u202f150\u202fmillion<\/strong> (\u2248\u202fUS$21\u202fmillion) from its cash reserves to accelerate the BIOS\u20110625 program, with additional financing under consideration for later\u2011stage trials.<\/li>\n\n\n\n<li><strong>Share Reaction:<\/strong> Bio\u2011Sincerity\u2019s A\u2011shares rose <strong>\u2248\u202f3.2\u202f%<\/strong> in early trading following the announcement, reflecting investor optimism about the pipeline\u2011centric milestone.<\/li>\n\n\n\n<li><strong>Outlook:<\/strong> Successful Phase\u202fI\/II outcomes could enable <strong>global IND submissions<\/strong> and open pathways for <strong>co\u2011development or licensing<\/strong> deals, potentially adding <strong>multi\u2011billion\u2011dollar<\/strong> valuation upside.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the development timeline, regulatory expectations, and commercial potential of BIOS\u20110625. Actual results may differ due to risks including clinical trial outcomes, regulatory approvals, and market acceptance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hangzhou Bio\u2011Sincerity Co., Ltd. (SHE: 301096) announced today that its BIOS\u20110625 tablet, a Class\u202f1 small\u2011molecule&#8230;<\/p>\n","protected":false},"author":1,"featured_media":46294,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[4372,62,3975],"class_list":["post-46293","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-biosincerity","tag-clinical-trial-approval-initiation","tag-she-301096"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hangzhou Bio\u2011Sincerity Secures NMPA Approval for BIOS\u20110625 Tablet \u2013 First\u2011in\u2011Class Ulcerative Colitis Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hangzhou Bio\u2011Sincerity Co., Ltd. (SHE: 301096) announced today that its BIOS\u20110625 tablet, a Class\u202f1 small\u2011molecule innovative drug, has received clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for the treatment of ulcerative colitis (UC).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=46293\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hangzhou Bio\u2011Sincerity Secures NMPA Approval for BIOS\u20110625 Tablet \u2013 First\u2011in\u2011Class Ulcerative Colitis Therapy\" \/>\n<meta property=\"og:description\" content=\"Hangzhou Bio\u2011Sincerity Co., Ltd. (SHE: 301096) announced today that its BIOS\u20110625 tablet, a Class\u202f1 small\u2011molecule innovative drug, has received clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for the treatment of ulcerative colitis (UC).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=46293\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-11T03:21:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-11T03:21:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1102.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46293#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46293\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hangzhou Bio\u2011Sincerity Secures NMPA Approval for BIOS\u20110625 Tablet \u2013 First\u2011in\u2011Class Ulcerative Colitis Therapy\",\"datePublished\":\"2025-11-11T03:21:15+00:00\",\"dateModified\":\"2025-11-11T03:21:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46293\"},\"wordCount\":336,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46293#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1102.webp\",\"keywords\":[\"Bio\u2011Sincerity\",\"Clinical trial approval \\\/ initiation\",\"SHE: 301096\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46293#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46293\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=46293\",\"name\":\"Hangzhou Bio\u2011Sincerity Secures NMPA Approval for BIOS\u20110625 Tablet \u2013 First\u2011in\u2011Class Ulcerative Colitis Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46293#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46293#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1102.webp\",\"datePublished\":\"2025-11-11T03:21:15+00:00\",\"dateModified\":\"2025-11-11T03:21:16+00:00\",\"description\":\"Hangzhou Bio\u2011Sincerity Co., Ltd. (SHE: 301096) announced today that its BIOS\u20110625 tablet, a Class\u202f1 small\u2011molecule innovative drug, has received clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for the treatment of ulcerative colitis (UC).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46293#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46293\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46293#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1102.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1102.webp\",\"width\":1080,\"height\":608,\"caption\":\"Hangzhou Bio\u2011Sincerity Secures NMPA Approval for BIOS\u20110625 Tablet \u2013 First\u2011in\u2011Class Ulcerative Colitis Therapy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46293#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hangzhou Bio\u2011Sincerity Secures NMPA Approval for BIOS\u20110625 Tablet \u2013 First\u2011in\u2011Class Ulcerative Colitis Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hangzhou Bio\u2011Sincerity Secures NMPA Approval for BIOS\u20110625 Tablet \u2013 First\u2011in\u2011Class Ulcerative Colitis Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"Hangzhou Bio\u2011Sincerity Co., Ltd. (SHE: 301096) announced today that its BIOS\u20110625 tablet, a Class\u202f1 small\u2011molecule innovative drug, has received clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for the treatment of ulcerative colitis (UC).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=46293","og_locale":"en_US","og_type":"article","og_title":"Hangzhou Bio\u2011Sincerity Secures NMPA Approval for BIOS\u20110625 Tablet \u2013 First\u2011in\u2011Class Ulcerative Colitis Therapy","og_description":"Hangzhou Bio\u2011Sincerity Co., Ltd. (SHE: 301096) announced today that its BIOS\u20110625 tablet, a Class\u202f1 small\u2011molecule innovative drug, has received clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for the treatment of ulcerative colitis (UC).","og_url":"https:\/\/flcube.com\/?p=46293","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-11T03:21:15+00:00","article_modified_time":"2025-11-11T03:21:16+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1102.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=46293#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=46293"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hangzhou Bio\u2011Sincerity Secures NMPA Approval for BIOS\u20110625 Tablet \u2013 First\u2011in\u2011Class Ulcerative Colitis Therapy","datePublished":"2025-11-11T03:21:15+00:00","dateModified":"2025-11-11T03:21:16+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=46293"},"wordCount":336,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=46293#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1102.webp","keywords":["Bio\u2011Sincerity","Clinical trial approval \/ initiation","SHE: 301096"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=46293#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=46293","url":"https:\/\/flcube.com\/?p=46293","name":"Hangzhou Bio\u2011Sincerity Secures NMPA Approval for BIOS\u20110625 Tablet \u2013 First\u2011in\u2011Class Ulcerative Colitis Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=46293#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=46293#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1102.webp","datePublished":"2025-11-11T03:21:15+00:00","dateModified":"2025-11-11T03:21:16+00:00","description":"Hangzhou Bio\u2011Sincerity Co., Ltd. (SHE: 301096) announced today that its BIOS\u20110625 tablet, a Class\u202f1 small\u2011molecule innovative drug, has received clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for the treatment of ulcerative colitis (UC).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=46293#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=46293"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=46293#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1102.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1102.webp","width":1080,"height":608,"caption":"Hangzhou Bio\u2011Sincerity Secures NMPA Approval for BIOS\u20110625 Tablet \u2013 First\u2011in\u2011Class Ulcerative Colitis Therapy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=46293#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hangzhou Bio\u2011Sincerity Secures NMPA Approval for BIOS\u20110625 Tablet \u2013 First\u2011in\u2011Class Ulcerative Colitis Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1102.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46293","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=46293"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46293\/revisions"}],"predecessor-version":[{"id":46295,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46293\/revisions\/46295"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/46294"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=46293"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=46293"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=46293"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}